Lack of Employment and the Absence of a Stable Partnership Are Independent Risk Factors for Hospitalization or Death among HIV Patients on HAART  

In the HAART era, in economically-advanced western nations, HIV infection has become a condition in which non-specific morbidity has played an increasing role in the overall morbidity and mortality of people with chronic HIV disease. The health status of HIV patients increasingly is influenced by factors such as adherence, co-morbidity, and level of social support.

Despite the effectiveness of anti-HIV therapy, HIV patients are at considerable risk for hospitalization, which French researchers recently have determined is significantly impacted by the patients’ socio-economic situation. Their study results, published in the current issue of JAIDS (October 1, 2005), demonstrates that socio-economic factors, such as not having a stable relationship and lack of a permanent job, are risk factors for hospitalization or death much earlier in the course of HIV infection than would be expected.

“In France, write the study authors, “access to care for HIV infection is universal. In the HAART era, HIV infection has been mostly managed through outpatient clinics, and inpatient admissions have been limited to the most serious cases. Thus, the indicator constituted by all-cause hospitalization or death is likely to represent a valid marker of HIV-infected patients' global health deterioration.”

The aim of this study was to estimate the independent association between socio-economic situation and the risk of all-cause hospitalization or death during the course of HIV in the HAART era.

Patients in the French PRIMO multicenter prospective cohort of 319 individuals were enrolled during primary HIV-1 infection between 1996 and 2002. Associations between social characteristics (ie, employment status, stable partnership) and the risk of hospitalization or death were assessed using generalized estimating equations.

Results

During a median follow-up of 2.5 years, 109 hospitalizations among 84 patients (26.3%) and 3 deaths occurred.

Even after adjustment for classic determinants of HIV-infected patients' health status, social characteristics were independently associated with the risk of hospitalization or death, with a significantly increased risk for patients with temporary employment compared with those with stable employment and for patients without a stable partnership compared with those with a stable partnership.

The authors conclude, “In the era of HAART, adverse social conditions constitute independent risk factors of hospitalization or death during the course of HIV disease.”

Discussion

Overall, greater than 25 percent of the study participants were hospitalized at least once during a median follow-up period of 2.5 years,. This rate seems unusually high in a population of young, recently HIV-infected, non hepatitis C coinfected, HAART-treated patients. “The persisting high risk of inpatient admission in the HAART era reported among ethnic minorities and injection drug users therefore also seems to occur among more socially privileged patients,” note the authors.

At 21.3 percent, the number of hospital admissions determined by mental disorders was also high. The result indicating that the risk of hospitalization or death is higher during the first year of follow-up compared with the later period was unexpected. “As suggested by sociologic studies, the biographical disruption consecutive to a diagnosis of chronic illness may lead to a period of increased social and health vulnerability,” according to the researchers.

“In conclusion,” write the authors, “in the era of HAART, the risk of hospitalization is high from the first months of HIV disease. Early psychologic support should seek to prevent a portion of these hospitalizations occurring at the early stages of the disease.”

“Adverse social conditions, namely, temporary employment and the absence of a stable partnership, constitute independent risk factors of poor health status as defined by all-cause hospitalization or death among HIV-infected patients.”

“Further studies with more detailed data on patients' living conditions should provide a better understanding of the mechanisms of such social health inequalities in this specific context.”

10/05/05

Reference
R Dray-Spira and others (for the the PRIMO Cohort Study Group). Temporary Employment, Absence of Stable Partnership, and Risk of Hospitalization or Death during the Course of HIV Infection. Journal of Acquired Immune Deficiency Syndromes 40(2):190-197, October 1, 2005.

Link to FDA-approved Anti-HIV Drugs
PI
NRTI
nNRTI
EI
Combivir
Emtriva
Epivir
Epzicom
Hivid
Retrovir
Trizivir
Truvada
VIDEX
VIDEX EC  
Viread

Zerit
Zerit XR
Ziagen
Rescriptor
Sustiva
Viramune
Fuzeon
Protease Inhibitors
Non Nucleoside Reverse Transcriptase Inhibitors
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
Entry / Fusion Inhibitors
Link to Experimental Medicines in Development for AIDS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

HIV/AIDS Topics
 [ A to Z ]

Abacavir Sensitivity Reaction
Acquired Drug Resistance
Acquired Rectal Fistula

Adherence
Adolescents
African Americans
Age/aging
AIDS-defining Illnesses
AIDS-related Non-Hodgkin's Lymphoma
Alcohol
Alternative Therapies
ALT/AST
Anal Intraepithelial Neoplasia (AIN)
Anemia / Fatigue
Antimycobacterial Prophylaxis
Atheroschlerosis
Aspergillosis
Autoimmune Thyroid Disease
Bacteremia
Bacterial Infections
Bartonella
Body Mass Index (BMI)
Bone Disorders
Boosted Protease Inhibitors
Breast-feeding
Buffalo Hump (BH)
Caesarean section
Candidiasis
Cancers
Cardiovascular Disease
CXCR4 Co-receptor
CCR5 Co-receptor
CD4 T Cell Count/ Percent
CD4+ and CD8 in Whole Blood
CD8+ T Cell
CD8 and CD3 Cells
Cerebrospinal Fluid (CSF)
Cholesterol / Triglycerides
Children and Infants
Central Nervous System (CNS)
Clinical Trials
CMV Retinitis
Complementary Alternative Therapies
Cosmetic Procedures
CYP3A Pathway
Cryptococcus
Cytomegalovirus
Dementia
Depression
Developing Countries
Diabetes
Diarrhea / Gastrointestinal
Dietary Intake
Directly Observed Therapy (DOT)
Disease Progression
Dosing
Drug Abuse
Drug Interactions
Drug Pricing
Drug Resistance Testing
Dyslipidemias
Elevated bilirubin and Jaundice
Elevated Creatinine Level
Entry Inhibitors
Epstein Barr Virus
Epidemiology
Eradication (HIV)
Ethnicity
Experimental Drugs
Experimental Vaccine
Facial Implants
Fat Loss
Fat Accumulation
Fat Redistribution
FDA-Approved Treatments
Fixed-dose Combinations (FDC)
Flu / Fever
Fungal Infections
Fusion or Entry Inhibitors
GB Virus C (GBC of hepatitis G)
Gender
Generics
Genetics
Genotype Resistance Testing
Glucose MetabolismInsulin Resistance
Growth Failure
Growth Hormone
Guidelines
Gynecomastia
HAART / Mega-HAART
Hairy leukoplakia
Hepatotoxicity (Liver Toxicity)
Hispanic Ethnicity
Histoplasmosis
HIV Antibody
HIV Eradication
HIV Prevalence
HIV Proviral DNA Testing
HIV p24 Antigen
HIV-related Adverse Events
HIV Replication
HIV RNA and HIV bDNA Testing
HIV Therapeutics
HIV-1 Fitness Assay
Hodgkin's Disease
Hormone Therapies
Hospice Care
Human Herpesvirus 8 (HHV-8)
Humanpapillomavirus (HPV)
Hydroxyurea (HU)
Hyperlactatemia
Hyperlipidemia
Hypersusceptibility
Hyperbilirubinemia / Jaundice
Hypertension
Hypophosphatemia
Hypothyroidism
Immunotherapy
Immune Based Therapy
Immunosuppression
Immune Restoration Disease
Immune Reconstitution Disease (IRD)
Immune Reconstitution Inflammatory Syndrome (IRIS)
Infants
Infective Endocarditis
Injection Site Reactions
Insulin Resistance
Intensification Therapy
Injection Drug Users (IDU)
Integrase Inhibitors
JC Virus
Kaposi Sarcoma
Kidney Toxicity / Failure
Kinetic PCR
Lactic Acidosis/Hyperlactatemia
Leukoencephalopathy
Lipid Abnormalties
Lipodystrophy
Liver Enzyme
Long-term Non Progression
Lung Diseases
Non-Tuberculosis Lung Diseases
Malignancies
Mega-HAART
Men Who Have Sex with Men (MSM)
Meningoencephalitis
Microbicides
Miscellaneous
Mitochondrial Toxicity
Morphologic Changes
Mortality and Morbidity
Mother-to-Child Transmission
Multidrug Resistant (MDR) HIV
Mutation Resistance
Myalgias (muscle aches)
Mycobacterium avium Complex
Myelopathy
Myocardial Infarction (MI)
Natural History
NAMs
(nucleoside-associated resistance mutations)

Nausea
Neonatal Transmission
Nephrotoxicity
Neopterin
Neurotoxicity
Neutropenia
Nevirapine-associated Rash
Nitazoxanide
Nucleic Acid Screening Test
Non-AIDS Related Hodgkin's Lymphoma
Non-Tuberculosis Lung Diseases
Non-Nucleoside Reverse Transcriptase Inhibitors (nNRTIs)
Non-occupational Post Eexposure Prophylaxis (NPEP)
NNRTI Toxicities and Side Effects Guide
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)
Nutrition
Opportunistic Infections (OIs)
Oral OIs/ hairy leukoplakia/ warts
Pain
Palliative Care
Pancreatitis
Parasites
Pathogenesis

Pediatrics
Peripheral Neuropathy
Perinatal Transmission
Pharmacokinetics

Pharmacodynamics
Pneumonia
Pneumocystis carinii pneumonia (PCP)
Phenotype Resistance Testing
Pharmacokinetics
Progressive Multifocal Leukoencephalopathy (PML)
Pheumonia
Physical Exercise
Positron Emission Topography
Protease Assay
Proteinuria and Elevated Creatinine Level
Psychiatric (mental)
PML
Post Exposure Prophylaxis (PEP)

Post-traumatic Stress Disorder (PTSD)
Pregnancy
Prevention
Primary HIV Infection
Protease Inhibitors (PIs) / Boosted PIs
Protease Inhibitor Toxicities/Side Effects (PDF)
Public Policy
Quality of Life

Race / Ethnicity
real-time DNA PCR (RT DNA-PCR)
Renal (Kidney) Toxicity / Failure
Replication Capacity Tests
Resistance
Resistance Mutation
Resistance Testing
Resistance Training
Ritonaivr Boosted PIs
Safer Sex
Salvage Therapies
Seroconversion
Severe Adverse Drug Reactions
Sexual Dysfunction
Sexually Transmitted Diseases
Side Effects
Simplification Regimens/Trials
Skin Conditions
Smoking
Staphylococcus Aureus
Steroids
Stroke
Substance Abuse
Suicidal Ideation
Survival
Super Infection
Sustained Virological Response
Syphilis
Switch Studies
TAMs (thymidine analogue mutations)
Tat gene
Testosterone
thrombosis
Therapeutic Drug Monitoring (TDM)
Therapeutic HIV Vaccines
Thyroid Disease
Toxicities and Side Effects
Toxicities Guides
Toxoplasmosis
Transmission

Transplantation
Treatment Failure
Treatment Guidelines
Treatment Interruptions (TIs)
Tuberculosis
Undetectable HIV Viral Load
Unsafe Sex
Vaccines
Vaginal HIV Shedding
Vertical Transmission of HIV
Viral (HIV) Set Point
Viral Load (HIV RNA or HIV bDNA)
Viral Load Rebound / Increase
Virco Antivirogram
Virologic Control
Virologic Failure
Visceral Adiposity
Virtual Phenotype Resistance Testing
Wasting - HIV
White Race / Caucasian
Women